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Summary. Anti-factor Xa and anti-thrombin activities of
unfractionated (UF) and low molecular weight (tMW)
heparins have been measured in human plasma and with
purified human antithrombin III (ATIII) in the absence and
presence of 1'5 mu calcium. The anti-factor Xa and anti-
thrombin activities were measured directly, by assessing the
heparin-dependent pseudo-first order rate constants of inacti-
vation of human factor Xa or thrombin. These activities were
studied with the 4th International Standard for UF heparin,
the lst International Standard for LMW heparin, C'1216,
enoxaparin, Cy222, and the synthetic pentasaccharide' In
plasma, calcium equally well increased the specific anti-
factor Xa catalytic activities as compared to purified ATIII'
That is, 1 '5 mu calcium stimulated the UF standard heparin-
catalysed inactivation of factor Xa 2'L-2'4 times' In the
presence of the LMW heparins the effect of calcium was
smaller (1 '3-1 '7 times), and in plasma there was no effect of
calcium on the pentasaccharide-catalysed inactivation of
factor Xa. Thus, the largest effects of calcium in the
inactivation reaction of factor Xa is seen with UF standard
heparin. Calcium reduced the anti-thrombin activities of all
the heparin preparations studied about 1'5 times when
purified ATIII was used, although in plasma this effect was
less clear. Consequently, in the presence of 1'5 mlu calcium
the ratio of the anti-factor Xa to the anti-thrombin activities
of UF standard heparin approximated those of the LMW
heparins. The only exception was CY222, which under all
conditions retained anti-factor Xa/anti-thrombin ratios sig-
nificantly higher than those ofUF standard heparin'
One of the regulatory mechanisms of blood coagulation is the
inhibition of enzymes of the coagulation system by the
plasma protein antithrombin III (ATIII)' its main targets in
clotting plasma being thrombin and factor Xa (Harpel'
1987). Inactivation ofthese serine proteases is catalysed by
heparin, and thus the heparin-dependent anti-factor Xa and
anti-thrombin activities have become main points of interest
in studying the mode of action and the standardization of
heparin. It should also be noted here, however, that the
ATlll-dependent inactivation of free factor fXa can contri-
bute significantly to the heparin effect in clotting plasma
(B6guin et al, l99l).
Since 1976 it is known that low molecular weight (LMW)
heparin fractions have little effect on tests of overall clotting'
such as the activated partial thromboplastin time (APTT)' but
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maintain their potency as measured by anti-factor Xa assays
(Andersson et al, 1976: Lane et al, 1978: Barrowcliffe et al,
1979). Studies on the structure-function relationship of
heparin have learned that a pentasaccharide sequence,
necessary for the interaction with ATIII, is sufficient to obtain
catalysis of the inactivation of factor Xa (Choay, 1989)' The
heparin-catalysed inactivation of thrombin is dependent on
the simultaneous binding of both proteins, which requires a
heparin chain length of at least 1 8 saccharide units (Lane et
aL 7984t Danielsson et aI, 1986). LMW heparin preparations
consist of chains with a length ol 2-30 saccharides' Thus
they contain considerable amounts of material without anti-
thrombin activity, and therefore their lower anticoagulant
activities in APTTlike tests are thought to be caused by
reduced anti-thrombin specific activities. Subsequently, it has
become generally accepted that LMW heparin preparations
differ from unfractionated (UF) heparin preparations by
significant higher anti-factor Xa to anti-thrombin ratios'
At present (LMW) heparin-dependent anti-factor Xa and
anti-thrombin activities are mostly assessed in a non-
recalcified citrated plasma milieu, because factor Xa and
thrombin generation should not interfere with the measure-
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ment of the exogenously added enzymes. Very often bovine
factor Xa is used. It must be appreciated, however, that
ionized calcium can interfere with the protein-heparin
interactions taking place (Braud et al, 1980). Indeed, in
reaction systems composed of purified proteins it has been
demonstrated that calcium reduces the rate constants of
inactivation of thrombin (Speight & Griffith, 1983), whereas
it enhances the inactivation of factor Xa (Barrowcliffe &
Shirley, 1989; Schoen et aI, 1989). The latter effect is
especially important in the case of human factor Xa, and the
extent of this effect depends on the heparin molecular size. In
addition, the anti-factor Xa and anti-thrombin activities
assayed are expressed relative to those of a UF reference
preparation (U/mg), of which the anti-factor Xa and anti-
thrombin activities are per definition equal, or relative to a
LMW reference preparation which has been calibrated
against the UF reference preparation (Barrowcliffe et al,
1988). This approach tends to obscure the fact that in
practice thrombin is inhibited much faster than factor Xa.
The point which has to be addressed at present is, to what
extent does ionized calcium in the physiological range, and
the presence ofplasma proteins influence the rate constants
of inactivation of factor Xa and thrombin, and the ratios of
these rate constants. Therefore, we extended our previous
study with purified ATIII (Schoen et aI, 199I\, and investi-
gated the (LMW) heparin-dependent rate constants of inacti-
vation of factor Xa and thrombin in the absence and presence
of 1 '5 mlt calcium, in a purified system and in normal human
plasma.
MATERIALS AND METHODS
The 4th International Standard for heparin (UF standard
heparin) and the lst International Standard for LMW
heparin (LMW standard heparin) were a kind gift of Dr T. W.
Barrowcliffe from the National Institute for Biological Stan-
dards and Control (Potters Bar, U.K.). The LMW heparin
preparations Cy21.6 (batch P 795 XH), CY222 (batchP 227
WH), and the synthetic pentasaccharide (Choay et aI, 1983))
were from Sanofi Recherche (Gentilly, France). Enoxaparin
was from Rh6ne-Poulenc (Gennevilliers, France). Mean
molecular weights, and anti-factor Xa and anti-thrombin
potencies (U/mg) of these heparin preparations are given in
Table I.
Normal platelet free plasma was prepared as described
previously (Hemker et al, 1986). Human factor Xa and
human ATIII were prepared as described previously (Schoen
et al, 7990). Thrombin was isolated by chromatography of
prothrombinase-activated human prothrombin on sulpho-
propyl-Sephadex (Pharmacia, Uppsala, Sweden), atpH 7.4
(Miller-Andersson et al, 1980). The molar concentrations of
the factor Xa and thrombin preparations were determined by
active site titrations with p-nitrophenyl-p'-guanidinoben-
zoate.HCl (Chase & Shaw, 1969; Smith, 1973). The molar
concentration of the ATIII preparation was assessed by
titration with known amounts of factor Xa. The proteins were
stored in 50 mu Tris-HCl (pH 7'9), containing 175 mnr NaCl,
at -7O"C.
Chromo genic substrates forfactorXa, benzoyl-r,-isoleucyl-r,-
Table L Mean molecular weights, and specific potencies
heparin preparations used in this study.
of the
Heparin*
a-Xa a-IIa
activity activity
(U/mg) (U/mg) a-Xa/a-IIa
IJF St. Hep.$
LMW St. Hep.*
cY2165
Enoxaparin$
cY222n
Pentasaccharide$
12500 793
6400 168
5100 95
3800 98
3800 53
7775 rI40
1 9 3  1 . 0
6 7  2 . 5
2 7  3 . 5
2 5  3 . 9
7  7 . 6
0 o o
* Abbreviation: St. Hep., standard heparin.
t Determined by gel permeation HPLC, or in the case ofpentasac-
charide deduced from its chemical composition (Choay et aI, 1983).
+ Anti-factor Xa and anti-thrombin activities as supplied by the
National Institute for Biological Standards and Control (Potters Bar,
u.K.).
$ Anti-factor Xa and anti-thrombin activities related to those of the
LMW standard heparin (International Units/mg; persona-l comrnuni-
cation, Dr T. W. Barrowclifle).
tl Anti-factor Xa and anti-thrombin activities related to those of
the LMW standard heparin (Cadroy et a\,7989).
glutamyl - (y - piperidyl) - r, - glycyl - r, - arginine - p - nitroanilide .
HCI (S2337) and thrombin, o-phenylalanyl-r,-pipecolyl-r,-
arginine-p-nitroanilide. 2HCl (S22 38) were purchased from
AB Kabi Diagnostica (Stockholm, Sweden). Recombinant
desulphato-hirudin variant 1 (CGP39393) was kindly pro-
vided by Dr R. Wallis from Ciba-Geigy Pharmaceuticals
(Horsham, U.K.)
Inactivation of factor Xa and thrombin by purified ATIIL The
heparin-catalysed inactivation of factor Xa and thrombin by
purified ATIII was studied underpseudo-first order conditions
at 3 7oC. Either of the enzymes was added to a mixture of ATIII
and heparin in 50 mu Tris-HCl (pH 7.9), containing 175 mu
NaCl and 0.5 mg/ml human serum albumin (HSA), either in
the absence or presence of I'5 mru CaCI2. The initial protease
and inhibitor concentrations were 30 nlr and 0.50 rlM.
respectively.
Following the addition of factor Xa or thrombin, four
samples of 2O pl each were removed within 1 min. The
residual factor Xa or thrombin activities were assayed by
adding the samples to cuvettes containing 43O pI of 50 ml-
Tris-HCI (pH 7'9), containing 175 mlr NaCl, 2O mv EDTA,
and 0'5 mg HSA/ml, and 50 plof 2.2 mu of either 52337 or
52238. The conversion of chromogenic substrate was fol-
lowed at 37oC on a dual wavelength spectrophotometer at
405 nm (reference wavelength 500 nm), and the residual
factor Xa and thrombin coqcentrations were calculated from
standard curves of known amounts of the enzymes. Due to
the 25-fold dilution of the samples, and the presence of excess
chromogenic substrate in the cuvettes, the rates of factor Xa
and thrombin neutralization became sufficiently low not to
result in measurable loss of enz5rmatic,activities during the
recording of the absorbances. The residual factor Xa and
thrombin activities were plotted exponehtially versus reac-
\
\
M.t
tion times, and the slopes (pseudo-first order rate constants)
of the linear plots thus obtained were determined by linear
regression analysis.
Inactivation of factor Xa and thrombin in plasma. Citrated
plasma (I27 .5 pl) was supplemented with a small aliquot of
heparin, plus 3.0 pl hirudin in the case of factor Xa
inactivation, and the volume was adjusted to ),40 plwith 50
mu Tris-HCl (pH7.9), containing 175 mu NaCl, and 0.5 mg
HSA/ml. After a 4 min incubatio n at 37"C, 10 pl factor Xa or
thrombin with or without CaCl2 was added to final concen-
trations of 30 nlr factor Xa or 50 nu thrombin, and 1.5 mu
free Ca2+ in 85% plasma. It was assessed with a calcium-
specific electrode system (Radiometer, Copenhagen, Den-
mark) that in order to obtain such a level of ionized calcium,
CaCl2 had to be added to the citrated plasma to a final
concentration of 15'5 mlr. Within 1 min, timed samples of
2O pl, each were removed and assayed for residual factor Xa
or thrombin as outlined above.
In factor Xa inactivation experiments in plasma, activation
of prothrombin, followed by feedback activation of factor V
could occur. The large amounts of thrombin formed subse_
quently, would lead to significant consumption of plasma
ATIII. Therefore, in these experiments hirudin (flnal concen-
tration 2.0 pM) was used to prevent clotting and consump-
tion of ATIII. In the thrombin inactivation experiments a
flbrin clot would be formed, seriously hampering sampling of
the plasma. Therefore in the case of thrombin inactivation,
defibrinated plasma (Hemker et aI, 1986) was used. Control
experiments in the absence of exogenously added factor Xa
and thrombin verified that, under these conditions, both in
the absence or presence of added CaCl2, no measurable
generation of plasma factor Xa or thrombin occurred durins
at least 5 min.
Analysis of the inactivation of factor Xa and thrombin in
plasma. In plasma, factor Xa and thrombin are not only
inactivated by ATIII, but also by a2-macroglobulin. Inactiva-
tion by a2-macroglobulin complicates the analysis of the
inactivation curves, due to the fact that the a2-macroglobu_
lin/protease complexes have a residual amidolytic activity
towards the chromogenic substrates used. In the case of
factor Xa inactivation, however, the contribution of az-
macroglobulin/factor Xa to the amidolytic activity measured
within 1 min, can safely be neglected due to the low rate of
inactivation of exogenous factor Xa by plasma a2-macroglo_
bulin (k: 0.0 7 min- r; Jesty, 198 6). Therefore, residual factor
Xa activities were plotted exponentially versus reaction
times, and the slopes (pseudo-first order rate constant) ofthe
linear plots thus obtained were determined by linear regres-
sion analysis.
In the case of thrombin inactivation, the reaction with a2-
macroglobulin cannot be neglected. It has previously been
derived (Hemker et aI, 1986) that thrombin inhibition in
plasma is then described by:
A,: Ao [Ck, + (k1 -f k. - Ckr)e-rn+tz)\l(k, I k) (l)
where A, is the amidolytic activity at time f, and Ao is the
initial amidolytic activity. The rate constant k1 accounts for
the (heparin-catalysed) formation of inactive thrombin_
inhibitor complexes (thrombin-ATlll and thrombin-heparin
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cofactor II), and k2 is the rate constant ofthe reaction between
thrombin and c2-macroglobulin, where the formed complex
has a fraction (C) of the activity of free thrombin. parameter C
was regarded as non-adjustable, with a value of 0.56
(Hemker et a\,1986). The thrombin data obtained within the
1 min inactivation periods would not allow an accurate
simultaneous determination of the values of kr and kz,
therefore we first of all independently determined the value of
k2. Thrombin was added to plasma, and its inactivation was
followed for 5 min, revealing the a2-macroglobulin/thrombin
endlevel. Equation 1 was then fitted to the data by a Gauss-
Newton least squares algorithm (Duggleby, 1981) which
revealed values of ku:0'30+0.05 min 1, and kr:
O'54+0.11 min-l in the absence of ionized calcium and in
the presence of 1'5 mn ionized calcium, respectively (errors
represent SE values). Then we performed one-parameter fits,
utilizing the same algorithm, to our data obtained during the
1 min inactivation periods in the presence of heparin. This
resulted in the values of kr, the pseudo-first order rate
constants of heparin-catalysed inactivation of thrombin.
Specific anti-factor Xa and anti-thrombin catalytic activities. In
each reaction system the specific anti-factor Xa and anti-
thrombin catalytic activities were obtained by determining
the increases of the pseudo-first order rate constants offactor
Xa and thrombin per weight concentration of heparin. That
is, the pseudo-first order rate constants of inactivation of
factor Xa and thrombin were plotted versus the concentra-
tions of heparin, and the slopes of the linear plots thus
obtained were determined by linear regression analysis.
Between four and eight experiments were used to determine
the specific catalytic activities, and the reported errors
represent the SE values of the estimates.
RESULTS
Rate constants of inactivation of factor Xa and thrombin by
purified ATIII as function of heparin and calcium concentration
Pseudo-first order rate constants of the reactions between
purified ATIII and factor Xa or thrombin were determined as
outlined under Materials and Methods. Fig 1 shows examples
of rate constants of inactivation of thrombin obtained in the
absence of calcium and in the presence of 1.5 or 4.0 nu
calcium for increasing concentrations of UF standard
heparin. The other heparin preparations were tested in the
same manner, including the inactivation of factor Xa, and the
pseudo-first order rate constants ofthe inactivation reactions
were always linearly dependent on the heparin concentra-
tions. Slopes ofsuch plots, the specific anti-factor Xa and anti-
thrombin catalytic activities, are summarized in Table II.
The data in Table II show that the specific anti-factor Xa,
catalytic activity of UF standard heparin is 2 .4 times higher in
the presence of 1.5 mlr calcium. In contrast, the effect of
calcium on the anti-factor Xa activities of the LMW heparin
preparations and of the pentasaccharide is much less pro_
nounced. While Ca2+-ions enhance the heparin-catalysed
inhibition of factor Xa, they reduce the catalytic activity of
heparin in the reaction of ATIII with thrombin. The presence
of 1.5 mlr calcium reduces the specific anti-thrombin
catalytic activities about 1 .5 times. There is some variation in
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Fig l. Rate constants ofinactivation ofthrombin by ATIII as function
of UF standard heparin concentration. Human thrombin was added
to purified ATIII in the absence ofionized calcium (o ), in the presence
of 1.5 mu (a) or 4.0 mu (tr) calcium. Pseudo-first order rate
constants were determined for increasing concentrations of UF
standard heparin as outlined under Materials and Methods. Solid
lines were obtained by linear regression analysis of the data.
Table II. Heparin-catalysed inactivation offactor Xa and thrombin by
ourified ATIII.
k  (min- ] [ i ig lmt] -1)
Heparin No CaCl2 I .5 mnr Ca2+ Rat io+
the effect of calcium on the (LMW) heparin-catalysed inacti-
vation of thrombin, although no clear relation seems appar-
ent between the type of heparin and the effect of calcium.
Previous work with purified proteins (Schoen et aI, 1991)
was performed in the presence of 4.0 mlr calcium. Compara-
tive data obtained in the present work at this level of calcium
showed that no quantitative differences are observed
between the inactivation of factor Xa in the presence of 1'5 or
4'0 mu calcium. Increasing the calcium levels does, how-
ever, further reduce the specific anti-thrombin catalytic
activities. In the presence of 4.0 mlr calcium the anti-
thrombin activities were on the average about 2.1 times
lower than in the absence of calcium. Also in these cases no
apparent relation between the type of heparin and the extent
of the calcium eflect was noted.
Effect oJ calcium on the inactivation of lactor Xa and thrombin in
plasma
Following these results obtained with purified ATIII the
question was put forward whether in plasma the inactivation
of factor Xa and thrombin would also be sensitive to the
presence of ionized calcium. To this end pseudo-first order
rate constants of inactivation of factor Xa and thrombin were
determined for increasing heparin concentrations as de-
scribed under Materials and Methods. Fig 2 shows UF
standard heparin-dependent rate constants obtained in the
absence and presence of 1 .5 ml. calcium. The other heparin
preparations were tested in the same manner, and the specific
anti-factor Xa and anti-thrombin catalytic activities are
summarized in Table IIL
Also in plasma it is observed that in the presence of 1 '5 mM
calcium the specific anti-factor Xa catalytic activities are
higher than in the absence of calcium. Moreover, the extent
of this effect follows the same order as with purified ATIII
(Table II). That is, calcium has no effect on the pentasacchar-
ide-catalysed inactivation of factor Xa whereas the effect
increases to 2.1-fold for the UF standard heparin-catalysed
reaction. In contrast to these results. ionized calcium at a
concentration of 1.5 mu has only a very small influence, if
any, on the specific anti-thrombin catalytic activities in
plasma. The results could suggest that there is a small
reduction (1.1-1'3 times) of anti-thrombin activity in the
presence of CY222 and enoxaparin. This does not indicate,
however, that the inactivation of thrombin in plasma, in the
presence of UF and LMW standard heparin, and CY216 is
completely insensitive to the presence of calcium. When the
ionized calcium concentration was increased to 4.0 mlvr the
anti-thrombin catalytic activities decreased 1.4-1.S-fold
(data not shown).
Anti-Jactor Xal anti-thrombin ratios
In each reaction system the ratio ofthe specific anti-factor Xa
catalytic activity (min l[pg/ml]-l) to that of thrombin was
calculated for each heparin preparation. The data obtained
are shown in Table IV. With purified ATIII in the absence of
calcium the ratios gradually increase from 0.078 with UF
standard heparin to O.27 with CY222. Ionized calcium
reduces the specific anti-thrombin catalytic activities and
increases the specific anti-factor Xa activitities (Table II).
Inhibition of factor Xa
UF standard heparin
LMW standard heparin
CY276
Enoxaparin
CY222
Pentasaccharide
Inhibition of thrombin
UF standard heparin
LMW standard heparin
CY276
Enoxaparin
CY222
Pentasaccharide$
3 . 8 0  +  O . 1  0
1 . 7 5  +  0 . 0 3
0.96  +  0 .03
0 . 8 5  + O  0 2
o.69  +  0 .03
1 0 . 2  + 0 . 1
4 8 . 7  + 7 . r
20 .2  +  0 .8
7  20+O.79
6 . 2 5  + O . 0 5
2 ' 5 9  +  0 . 0 8
9 . 0 3 + 0  1 3
2  9 1 + O . 0 1
1  . 5 8  +  0 . 0 1
1 . 4 5  +  0 . 0 1
l . l 0  +  0 . o 2
1 3 . 8  +  0 . 2
3 I . 2 + I . 2
7 3 ' 7  + O . 6
4 . 7 I + O . 1 3
4 64+O.O9
1 . 9 2  + 0 . 0 8
2 . 4
t 7
1 . 6
1 . 6
1 . 4
o 6 4
0.68
0 . 6 5
o ' 7 4
o.74
Human factor Xa or thrombin was added to purified ATIII either in
the absence of calcium or in the presence of 1 .5 mnr calcium. Heparin
concentrations were variable. The pseudo-ffrst order rate constants
of inactivation of factor Xa and thrombin were normalized to the
heparin concentrations. See Materials and Methods for further
experimental details. S At the highest concentration used to measure
pentasaccharide-catalysed inactivation of factor Xa (O. 5 pg/ml), the
rate constants of inactivation of thrombin were unaffected.
+ The ratio of the specific catalytic activities as obtained in the
presence of calcium to those as obtained in the absence of calcium.
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Fig 2' Rate constants of inactivation of factor Xa and thrombin in plasma as function of UF standard heparin concentration. Human factor Xa
(panel A) or human thrombin (panel B) was added to human plasma in the absence (o) or presence of 1.5 mu (a) ionized calcium. pseudo-fust
order rate constants were determined for increasing concentrations ofllF standard heparin as outlined under Materials and Methods. solid lines
were obtained by linear regression analysis of the data.
02 0.4 0.6
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Table III. Anti-factor Xa and anti-thrombin activities in human
plasma.
k (min-rfurg/mll 1)
Heparin No CaCl2 1. 5 mrrn Ca2 + Ratio* Heparin
0.1 02 0.3 0.4
UF Heparin (pgiml)
Table IV. Ratios of anti-factor Xa to anti-thrombin specific activities.
Purified ATIII Plasma
No
u a ' '
1.5 mu No 1'5 mrrl
Ca2+ Ca2+ Ca2+
Inhibition of factor Xa
UF standard heparin
LMW standard heparin
CY276
Enoxaparin
CY222
Pentasaccharide
Inhibition of thrombin
UF standard heparin
LMW standard heparin
CY2T6
Enoxaparin
cY222
Pentasaccharide$
Human factor Xa or thrombin was added to normal human
plasrna in the absence or presence of 1.5 mu calcium. Heparin
concentrations were variable. The pseudo,fust order rate consranrs
of inactivation of factor Xa and thrombin were normalized to the
heparin concentrations. See Materials and Methods for further
experimental details. $ At the highest concentration used to measure
pentasaccharide-catalysed inactivation of factor Xa (0. 5 pgl ml} the
rate constants of inactivation of thrombin were unaffected.
* The ratio of the specific catalytic activities as obtained in the
presence of calcium to those as obtained in the absence of calcium.
Consequently, calcium increases the anti-factor Xa/anti_
thrombin ratios. However, because the effect of calcium on
the heparin-catalysed inactivation of factor Xa is the most
pronounced with UF standard heparin, the ratio obtained
with this heparin preparation increases relatively more than
that of the lower molecular weightpreparations. Thus, in the
UF standard heparin
LMW standard heparin
CY276
Enoxaparin
cY222
0.078 0 .29  0 .15  0 .31
0.087 0 .2 I  O.27  0 .25
o . 1 3  0 . 3 4  0 . 2 7  0 . 3 7
o ' t4  0 .31  0 .25  0 .37
o . 2 7  0 . 5 7  0 . 5 0  0 . 7 7
Ratios of the specific anti-factor Xa and anti-thrombin catalytic
activities as determined with purified ATIII (Table II) and in plasma
(Table III), at variable concentrations of calcium.
presence of calcium the anti-factor Xa/anti-thrombin ratios
ofUF standard heparin, LMW standard heparin, Cy216, and
enoxaparin come closer to each other.
The latter observation is more clearly illustrated in Fig 3,
where the increases (or decreases) of anti-factor Xa to anti-
thrombin ratios are shown relative to the ratio as obtained
with UF standard heparin. With purified ATIII in the absence
of calcium, the ratios obtained with LMW standard heparin,
CY2I6, enoxaparin andCY222, increase by l2%, 6Z%,79%
and 246/o, respectively. In the presence of 1.5 mu calcium
the ratio as obtained with LMW standard heparin decreases
by 27%, and the ratios as obtained with Cy216 and
enoxaparin increase by L2/o and 7yo. The ultraLMW heparin
preparation Cy222 deviates from the other LMW heparin
preparations in that, although its ratio decreases due to the
presence of calcium, this parameter remains significantly
higher than that of UF standard heparin (increase by g7%).
In the plasma system in the presence of 1.5 mrvr calcium
the specific anti-thrombin activities are unaltered. However,
the specific anti-factor Xa activities are in the same manner
sensitive to calcium as with purified ATIII (Table III).
3 . 7 9  + O . 2 r
2 .48  +  0 .05
1 . 2 0 + 0 . o 1
0 '85  +  O '02
o.70+o.o2
1 1 . 0 + 0 . 4
2 5 . 9  + 0 . 5
rr .7 +o.4
4.45  +0.30
3.34  +  0 .06
1.40  +  0 .O7
7 . 9 7  + O . 2 2
3 ' 1 2  +  0 ' 0 5
1 . 6 1 + 0 . 0 3
I 'O9 +  0 'O3
0.86  +0.02
1 1 . 1  +  0 . 2
2 6 . I + O . 4
7 2 ' 6 + O . 3
4 '37  rO.28
2.95  +  0 .08
1.12+O.O7
2 . 7
1 . 3
1 . 3
1 . 3
7 . 2
1 . 0
1 . 0
1 . 1
0 .98
0.88
0 . 8
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Fig 3. Relative differences in antifactor Xa to anti-thrombin ratios. Increases (or decreases) of anti-factor Xa to anti-thrombin ratios are shown
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Therefore, also in plasma in the presence of 1.5 mlr calcium,
the anti-factor Xa to anti-thrombin ratios obtained with UF
standard heparin, LMW standard heparin, CY216, and
enoxaparin approach each other (Table IV, Fig 3). In the
absence of calcium, the ratios obtained with LMW standard
heparin, CY 216, enoxaparin and, CY 222, increase, respect-
ively,by 4O/o,8O%,67%and233lore\at ive to the rat io of UF
standard heparin. In the presence of 1'5 mu ionized calcium
the ratio as obtained with LMW standard heparin decreases
by 79%, and the ratios as obtained with CY216 and
enoxaparin both increase by 19%, relative to that of UF
standard heparin. Again in this system the ultra LMW
heparin preparation CY222 behaves different from the other
LMW heparin preparations: in the presence of 1'5 mu
calcium the anti-factor Xa to anti-thrombin ratio remains
significantly higher than that of UF standard heparin (in-
crease by I48%).
DISCUSSION
In the current laboratory tests designed to measure anti-
factor Xa and anti-thrombin activities, the activities of any
heparin preparation are expressed relatively to those of an
International Standard preparation. The unitage used is
U/mg, and it has been agreed that the anti-factor Xa and anti-
thrombin activities of the UF heparin standard preparations
are equal. Although this approach is relatively simple and
easy to comprehend, it gives no information about the true
inactivation rates obtained with heparins in the reaction with
factor Xa and thrombin. Moreover, as the relative activities of
heparin in plasma can vary both with the type of heparin and
the assay conditions this practice may introduce non-exiSting
differences between heparin preparations. Therefore we used
a standard independent method, i.e. the directly measurable
apparent first order rate constants ofinactivation offactor Xa
and thrombin, which give the absolute activities of the
heparin preparations under well-deflned conditions.
Following this approach we measured the heparin-cata-
lysed inactivation of human factor Xa and human thrombin
with purified human ATIII and normal human plasma, both
in the absence and presence of calcium at a level in the
physiologic range (1'5 mrur). Pseudo-flrst order rate constants
of inactivation of factor Xa and thrombin were determined as
function of the concentrations of heparin (cf. Figs 1 and 2)
which revealed the specific anti-factor Xa and anti-thrombin
catalytic activities (Tables II and III). In the case offactor Xa
inactivation in plasma, ATIII is the only inhibitor whose
activity is known to be catalysed by heparin. In this respect, it
is of interest to note that although the ATIII concentration
employed in the purified system is significantly lower than
the plasma ATIII concentration (0' 5 0 v. - 2 pw), comparable
specific anti-factor Xa activities were found for each heparin
in the two reaction systems. It therefore seems likely that
under both conditions all ATIII high-affinity binding sites
available on the heparin molecules are saturated with ATIII.
The latter notion could seem to contrast previous work by
others (Lane et al, 1984; MacGregor et aI, 1979, I98O).
However, Lane and co-workers used an ATIII concentration
of about 1 70 nu in their purified system, and compared these
data with a plasma system. In the work of MacGregor either
plasma was diluted 20-fold (ATIII :100 nu; MacGregor ef
aI, 79 7 9), or 5 7 nu ATIII was used (MacGre gor et al, 19 8O).
Thus, deviations between their and our results may be well
accounted for by differential experimental conditions.
In the case of thrombin inactivation in the absence of
calcium it is observed that the catalytic effects of the different
heparin preparations are in plasma about half of those
determined with purified ATIII, although plasma also con-
tains heparin cofactor II, which could contribute to the
heparin-catalysed inactivation of thrombin. The latter, how-
ever, seems to occur at heparin concentrations above those
employed in this work (Bray et al, 7989: Tollefsen ef al,
1990). It must be noted then, that the heparin-catalysed
ATlll-dependent inactivation of thrombin heavily depends
on the simultaneous binding of both proteins to the same
heparin molecule (Olson, 1988). It is well feasible, that due to
competition by other plasma proteins (e.g' histidine-rich
glycoprotein, vitronectin, and/or lipoproteins) the ATIII-
heparin-thrombin ternary complex formation is seriously
hampered in the plasma system in the absence of calcium.
Conversely, it is possible that calcium corrects for this effect,
as addition of calcium (1'5 mlt) reduces the diflerences
between the specific anti-thrombin catalytic activities in
plasma and with purified ATIII'
Calcium increases the heparin-dependent rate constants of
inactivation of factor Xa by purified ATIII' where no
quantitative difference is found between 1'5 and 4'0 nu
calcium. This is in accordance with previous work on the
effect of CaClz on the anti-factor Xa activity of heparin and its
molecular weight fractions, in which it was found that there
was an increase in potentiating effect between 0 and 1 mu,
with no further increase between 1 and 5 mlt (Barrowcliffe &
Shirley, 1989). In that study it was also reported that as the
number of heparin molecules with M.> 6500 increase, the
effect ofthe presence ofcalcium increases concomitantly. The
data in Table II are in the same line. As the mean molecular
weights increase, thus as the numbers of molecules with
M.>6500 increase, the potentiating effects of calcium
increase. There is, however, a major difference between the
observations made with oligosaccharides with M.<6000.
Whereas Barrowcliffe & Shirley (1989) demonstrated an
inhibitory effect of calcium on the catalytic activity of these
oligosaccharides, we failed to observe this with the CY222
preparation and the pentasaccharide, both in the presence of
1'5 and 4'0 mu calcium. Whether this is a fundamental
difference, or due to variability of the experimental settings is
unclear.
On the other hand, calcium in a concentration-dependent
manner inhibits the catalytic activity of heparin in the
reaction with thrombin. This is essentially identical to the
results of Speight & Griffith (1983), who also found a
concentration dependent effect ofcalcium in the inactivation
of thrombin with purified ATIII, when going from no calcium
to 10 mu calcium. In their work they concluded that calcium
binds to functional groups within the heparin molecule
which are required for thrombin binding. If this is the case
one could expect to find no major effect of heparin chain
length on the modulating eflect of calcium. Indeed this seems
to be the case (Table II).
Overall, with purified ATIII in the absence of calcium, and
in citrated plasma we obtained higher anti-factor Xa/anti-
thrombin ratios with the LMW heparin preparations than
with UF standard heparin. These differences, however, are
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smaller than those obtained with the current laboratory tests
(Table I). Although small, these differences decrease in the
presence of calcium at a concentration of 1'5 and 4'0 mn
(Table IV, Fig 3). Only the ultra LMW heparin CY222 shows
in the presence of calcium anti-factor Xa/anti-thrombin
ratios significantly higher than those of UF standard heparin.
From the specific anti-factor Xa and anti-thrombin catalytic
activities (Tables II and III) it follows that in essence these
observations are caused by the fact that calcium stimulates
the catalytic action of UF heparin on the inactivation of
human factor Xa to a larger extent than the catalytic action
of LMW heparin. It is therefore our conclusion that for in vitro
and er vivo testing ofheparin the use ofbovine clotting factors
in the absence of calcium and expressing the potencies
relative to those of a reference preparation, gives no relevant
information on the true anti-factor Xa and anti-thrombin
inactivation rates for (LMW) heparin preparations.
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